Frankfurt Stock Exchange

EQS-News: Supervisory Board and Executive Board recommend acceptance of delisting tender offer of Südzucker AG

Retrieved on: 
Tuesday, January 30, 2024

The Executive Board and Supervisory Board of CropEnergies consider the delisting to be in the best interest of CropEnergies.

Key Points: 
  • The Executive Board and Supervisory Board of CropEnergies consider the delisting to be in the best interest of CropEnergies.
  • Following a thorough and independent review of the offer document published on 17 January 2024, they support Südzucker’s public delisting tender offer.
  • “We support Südzucker’s public delisting tender offer and recommend that all shareholders accept the offer and tender their shares to Südzucker in good time.
  • The definitive terms of the delisting tender offer, as well as further provisions concerning the delisting tender offer, are set out in the offer document by Südzucker AG the publication of which has been approved by the German Federal Financial Supervisory Authority (BaFin).

EQS-News: DEAG announces its intention to Re-IPO on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange

Retrieved on: 
Tuesday, January 30, 2024

The Company targets a yearly organic revenue growth above market rates and continued unadjusted EBITDA margin expansion due to the highly profitable new Ticketing and Services segment.

Key Points: 
  • The Company targets a yearly organic revenue growth above market rates and continued unadjusted EBITDA margin expansion due to the highly profitable new Ticketing and Services segment.
  • Berlin, 18 January, 2024 — DEAG Deutsche Entertainment Aktiengesellschaft (the "Company" and, together with its subsidiaries, "DEAG"), one of Europe’s leading live entertainment service providers based on revenue, announces its intention to list its shares on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange in the first quarter of 2024, subject to market conditions.
  • With the help of its major shareholders, DEAG used the time during the pandemic to make important strategic decisions and implement them.
  • A smaller percentage of the proceeds will also be used to repay certain bank loans and for general corporate purposes.

EQS-News: Circus SE successfully starts trading on the Frankfurt Stock Exchange and XETRA listing

Retrieved on: 
Tuesday, January 30, 2024

Hamburg - January 22, 2024 - Circus SE (ISIN: DE000A2YN355 / WKN A2YN35) successfully completed its listing on Xetra on January 22, 2024 and, in connection with this, commenced trading on the Frankfurt Stock Exchange.

Key Points: 
  • Hamburg - January 22, 2024 - Circus SE (ISIN: DE000A2YN355 / WKN A2YN35) successfully completed its listing on Xetra on January 22, 2024 and, in connection with this, commenced trading on the Frankfurt Stock Exchange.
  • The Hamburg-based Circus Group is a company specializing in proprietary technology solutions in the fields of robotics, software engineering and artificial intelligence (AI).
  • In partnership with industry-leading partners, Circus has successfully tested and implemented its robotics and software solutions in various German cities since its founding in 2021.
  • Nikolas Bullwinkel, founder and CEO of Circus: "With the Xetra listing and the start of trading in Frankfurt, we are now also taking a decisive step on the capital market alongside the rapidly growing food service sector.

EQS-News: SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory

Retrieved on: 
Tuesday, January 30, 2024

“With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.

Key Points: 
  • “With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.
  • We will continue to benefit from key pharma trends and the overall market growth for injectable drugs”, said Almuth Steinkühler, CFO of SCHOTT Pharma.
  • In 2023, SCHOTT Pharma continued to deliver on its strategy and achieved several milestones along the pillars expansion and innovation.
  • On the innovation side, SCHOTT Pharma successfully introduced two leading innovations to the market that serve the pharma megatrends Glucagon-like peptide-1 (GLP-1) and mRNA.

EQS-News: Kontron acquires majority stake in Katek SE and expands leading position in the IoT market

Retrieved on: 
Tuesday, January 30, 2024

The buyer is the wholly owned German subsidiary Kontron Acquisition GmbH, which is acquiring the shares from the previous Katek majority shareholder PRIMEPULSE SE.

Key Points: 
  • The buyer is the wholly owned German subsidiary Kontron Acquisition GmbH, which is acquiring the shares from the previous Katek majority shareholder PRIMEPULSE SE.
  • Kontron expects the acquisition to significantly strengthen its own portfolio of renewable “green” energy solutions and the aerospace segment.
  • The Katek Group is a leading European electronics company that offers high-quality electronics and products in the fields of solar energy and e-mobility.
  • With the increased technological upgrade of Katek products, we expect Kontron’s net earnings to increase significantly in the medium term.”

EQS-News: Mutares places second tap issue of its bond issued in March 2023 with a volume of EUR 100 million and strengthens basis for further development

Retrieved on: 
Tuesday, January 30, 2024

Munich, January 19, 2024 – Today, Mutares SE & Co. KGaA (ISIN: DE000A2NB650) ("Mutares") has decided to increase its EUR 100 million bond issued in March 2023 with maturity on 31 March 2027 (ISIN: NO0012530965) and tapped by EUR 50 million in May 2023 ("Bond") through an optional Tap Issue by an amount of EUR 100 million ("Tap Issue").

Key Points: 
  • Munich, January 19, 2024 – Today, Mutares SE & Co. KGaA (ISIN: DE000A2NB650) ("Mutares") has decided to increase its EUR 100 million bond issued in March 2023 with maturity on 31 March 2027 (ISIN: NO0012530965) and tapped by EUR 50 million in May 2023 ("Bond") through an optional Tap Issue by an amount of EUR 100 million ("Tap Issue").
  • The Management Board of Mutares had decided to further increase the bond, given the opportunities on the buy-side and optimal market conditions.
  • The strategic move is based on Mutares' excellent positioning with a very robust and attractive pipeline in all regions.
  • The net proceeds from the tap issue will enable Mutares to take maximum advantage of the opportunities that arise on the buy-side.

EQS-News: Mutares positions newly formed HILO Group as system supplier of high-quality automotive technology

Retrieved on: 
Tuesday, January 30, 2024

Munich, January 25, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) is announcing the formation of another globally active automotive supplier operating under the name HILO Group.

Key Points: 
  • Munich, January 25, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) is announcing the formation of another globally active automotive supplier operating under the name HILO Group.
  • The newly founded holding company will consolidate Mutares' business for innovative precision components for OEMs, including hinges and locking systems.
  • HILO Group, as a leading global supplier of hinge and locking systems, within the Mutares Automotive & Mobility segment, will have a significant role in its future growth development.
  • Robin Laik, CEO of Mutares, comments: "I am very pleased to announce the formation of HILO Group as another globally active supplier for OEMs strengthening our Automotive & Mobility segment.

QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million

Retrieved on: 
Thursday, January 18, 2024

Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.

Key Points: 
  • Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.
  • The terms of the synthetic share repurchase are as follows:
    Every 25 issued QIAGEN shares will be consolidated into 24.25 QIAGEN shares, leading to a reduction of approximately 6.9 million shares from the level of 230.8 million shares at the end of 2023.
  • Following the implementation of the consolidation, QIAGEN will repay capital to shareholders of record in the amount of $1.28 per pre-split share.
  • (As the par-value of QIAGEN shares is denominated in euros, the amount of the capital decrease and repayment in the respective notarial deeds will also be denominated in euros.

EQS-News: Südzucker AG announces start of acceptance period for public delisting tender offer to shareholders of CropEnergies AG

Retrieved on: 
Wednesday, January 17, 2024

Delisting holds potential for improving liquidity and a revaluation of the Südzucker shares from which shareholders of CropEnergies can benefit through a re-investment in Südzucker.

Key Points: 
  • Delisting holds potential for improving liquidity and a revaluation of the Südzucker shares from which shareholders of CropEnergies can benefit through a re-investment in Südzucker.
  • Südzucker AG (“Südzucker”) announces the publication of the offer document for the public delisting tender offer to all shareholders of CropEnergies AG (“CropEnergies”) for the acquisition of all outstanding shares not already directly held by Südzucker, following the approval by the German Federal Financial Supervisory Authority (“BaFin”).
  • CropEnergies shareholders can accept the delisting tender offer by tendering their shares at an offer price of € 11.50 per share.
  • The executive board and supervisory board of CropEnergies will also publish a joint reasoned opinion on the delisting tender offer during the acceptance period.

Commerzbank AG: Announcement pursuant to Art. 5(1) lit. a) of Regulation (EU) No 596/2014 and Art. 2(1) of Delegated Regulation (EU) 2016/1052 / (Share Buyback Programme 2024)

Retrieved on: 
Saturday, January 13, 2024

2(1) of Delegated Regulation (EU) 2016/1052 / (Share Buyback Programme 2024)

Key Points: 
  • 2(1) of Delegated Regulation (EU) 2016/1052 / (Share Buyback Programme 2024)
    The issuer is solely responsible for the content of this announcement.
  • The purpose of the share buyback is the reduction of the share capital of Commerzbank AG.
  • The Share Buyback Programme 2024 will be carried out based on the authorization of the Annual General Meeting of Commerzbank AG on May 13, 2020.
  • The credit institution instructed with the purchase of shares of Commerzbank AG has been obligated accordingly by Commerzbank AG.